Prognostic utility of self‐reported sarcopenia (SARC‐F) in the Multiethnic Cohort

Wu, Anna H.; Setiawan, Veronica Wendy; Lim, Unhee; Tseng, Chiu-Cheng; White, Kami; Shepherd, John; Lenz, Heinz Josef; Cheng, Iona; Stram, Daniel O.; Haiman, Christopher A.; Wilkens, Lynne R.; Marchand, Loı̈c Le

doi:10.1002/jcsm.12916

Cited by 10 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARC‐F questionnaire is a widely used initial screening tool for sarcopenia and recommended by the AWGS and the European Working Group on Sarcopenia in Older People 27 . SARC‐F is suited for a rapid screening for sarcopenia in the setting like a community‐based large‐scale survey, and it was reported the significant association of higher score of SARC‐F with impaired physical function 28 and higher mortality risk 29 in the previous studies. However, recent studies treated with patients on dialysis therapy represented a poor association between SARC‐F score and skeletal muscle mass 30 and inadequate accuracy of SARC‐F for discriminating sarcopenia, which was defined using the AWGS2 criteria 9,30 .…”

Section: Discussionmentioning

confidence: 99%

Simplified discriminant parameters for sarcopenia among patients undergoing haemodialysis

Kakita

Matsuzawa

Yamamoto

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Patients with end-stage renal disease (ESRD) are at an increased risk of developing sarcopenia, which can lead to various adverse health outcomes. Although the diagnosis of sarcopenia is essential for clinical management, it is not feasible in routine clinical practice for populations undergoing haemodialysis because it is time-consuming and resources are limited. Serum creatinine levels in patients with ESRD have been gaining attention as a screening parameter for sarcopenia because serum creatinine is a routinely measured byproduct of skeletal muscle metabolism. This study aimed to evaluate the discriminative ability of the creatinine-derived index for sarcopenia in patients undergoing haemodialysis. Methods We diagnosed sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2 criteria in 356 clinically stable outpatients with ESRD enrolled from three dialysis facilities. We adopted the modified creatinine index as a simplified discriminant parameter for sarcopenia in addition to the calf circumference, SARC-F score, and combination of both (i.e. SARC-CalF score), which are recommended by the AWGS. Receiver operating characteristic analysis and logistic regression analysis were conducted to evaluate the discriminative ability of the modified creatinine index for sarcopenia. Results Of the study participants, 142 (39.9%) were diagnosed with sarcopenia. The areas under the curve of the modified creatinine index against sarcopenia in the male and female participants were 0.77 (95% confidence interval [CI]: 0.71 to 0.83) and 0.77 (95% CI: 0.69 to 0.85), respectively. All simplified discriminant parameters were significantly associated with sarcopenia, even after adjusting for patient characteristics and centre. In the comparison of the odds ratios for sarcopenia for 1-standard deviation change in the simplified discriminant parameters, the odds ratio of the modified creatinine index was 1.92 (95% CI: 1.15 to 3.19), which was lower than that of the calf circumference (odds ratio: 6.58, 95% CI: 3.32 to 13.0) and similar to that of the SARC-F (odds ratio: 1.57, 95% CI: 1.14 to 2.16) and SARC-CalF scores (odds ratio: 2.36, 95% CI: 1.60 to 3.47). Conclusions This study revealed a strong association between the creatinine-derived index and sarcopenia in patients undergoing haemodialysis. The modified creatinine index was equal or superior to those of SARC-F and SARC-CalF score in discriminability for sarcopenia. However, the ability of the calf circumference to discriminate sarcopenia is extremely high, and further study is needed to determine whether it can be used to detect deterioration of muscle mass and function over time.

show abstract

Section: Discussionmentioning

confidence: 99%

Simplified discriminant parameters for sarcopenia among patients undergoing haemodialysis

Kakita

Matsuzawa

Yamamoto

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…Thus, SARC-F seems to be very helpful for sarcopenia screening, although the sensitivity of SARC-F for sarcopenia is unsatisfactory low [3,19,36,37]. Additionally, SARC-F has recently been reported to be well correlated with all-cause mortality and all-cause-specific mortality [38].…”

Section: Discussionmentioning

confidence: 99%

Accurate SARC-F Score in Patients with Liver Disease

et al. 2023

View full text Add to dashboard Cite

SARC-F is a well-accepted screening tool for sarcopenia. A SARC-F value of 1 point is reported to be more discriminating in identifying sarcopenia than 4 points (recommended cutoff point). The prognostic impact of the SARC-F score was investigated in patients with liver disease (LD, n = 269, median age = 71 years, 96 hepatocellular carcinoma (HCC) cases). Factors associated with SARC-F ≥ 4 points and SARC-F ≥ 1 point were also examined. In the multivariate analysis, age (p = 0.048), and Geriatric Nutritional Risk Index (GNRI) score (p = 0.0365) were significant factors linked to SARC-F ≥ 1 point. In our patients with LD, the SARC-F score is well correlated with the GNRI score. The 1-year cumulative overall survival ratio in patients with SARC-F ≥ 1 (n = 159) and SARC-F 0 (n = 110) was 78.3% and 90.1% (p = 0.0181). After excluding 96 HCC cases, similar tendencies were found (p = 0.0289). In the receiver operating curve (ROC) analysis based on the prognosis for the SARC-F score, the area under the ROC was 0.60. The sensitivity was 0.57, the specificity was 0.62, and the optimal cutoff point of the SARC-F score was 1. In conclusion, sarcopenia in LDs can be affected by nutritional conditions. A SARC-F score of ≥1 is more useful than a score of 4 in predicting the prognosis of patients with LD.

show abstract

“…The measurement of muscle mass relies on instruments such as CT, MR, and dual-energy X-ray absorptiometry (DXA), which is not convenient for use in large-scale population screening. In recent years, different scales have been widely used in population screening due to their rapid and simple advantages, including the sarcopenia-five scale (SARC-F) 20 , SARC-F combined with calf circumference (SARC-CalF) scale 21 , and SARC-F adding elderly and body mass index (BMI) information scale (SARC-F + EBM) 22 , 23 , but those scales have difficulty taking into account the sensitivity and specificity of the diagnosis of sarcopenia. Therefore, the efficacy of those scales in the diagnosis or screening of sarcopenia still needs to be further verified.…”

Section: Introductionmentioning

confidence: 99%

Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18–59 years: a population-based study

Zhao,

Zeng,

Liang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The association between the systemic immune-inflammation index (SII) and the risk of sarcopenia has not yet been revealed. The purpose of this study was to investigate the relationship between the SII and sarcopenia in individuals aged 18–59 years. All data for this study are from the National Health and Nutrition Examination Survey (NHANES) database, including 7258 participants (age range: 18–59 years). We divided SII values by quartiles (quartiles 1–4: 0.3–3.1, 3.2–4.4, 4.4–6.2, and 6.2–58.5). We constructed a multivariate logistic regression model to assess the association between the SII and the risk of sarcopenia, and an interaction test was run to test the stability of the model and identify high-risk individuals with sarcopenia. Compared to nonsarcopenia participants, sarcopenia patients had a significantly higher SII value (weighted average: 6.65 vs. 5.16) (P = 0.002). Multivariate logistic regression results showed a positive linear relationship between the SII and sarcopenia (OR [odds ratio] = 1.12, 95% CI [confidence interval] 1.03–1.21). Compared to the quartile 1 group, the quartile 4 group was associated with a higher risk of sarcopenia (OR = 3.94, 95% CI 1.42–10.94). Compared with the quartile 1 group, the OR value of the quartile 2 to quartile 4 groups showed an upwards trend (Ptrend < 0.001) as the level of SII increased. Subgroup analysis also indicate that the correlation between higher SII values and the risk of sarcopenia was stable. There was a significant positive linear relationship between SII and sarcopenia, indicating that higher SII values can increase the risk of sarcopenia in individuals aged 18–59 in the United States. The findings of this study will be beneficial in promoting the use of SII alone or in combination with other tools for the risk screening of sarcopenia in communities or large populations.

show abstract

Prognostic utility of self‐reported sarcopenia (SARC‐F) in the Multiethnic Cohort

Cited by 10 publications

References 42 publications

Simplified discriminant parameters for sarcopenia among patients undergoing haemodialysis

Simplified discriminant parameters for sarcopenia among patients undergoing haemodialysis

Accurate SARC-F Score in Patients with Liver Disease

Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18–59 years: a population-based study

Contact Info

Product

Resources

About